Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis

  title={Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis},
  author={Bruno Romeo and Laurent Karila and Catherine Martelli and Amine Benyamina},
  journal={Journal of Psychopharmacology},
  pages={1079 - 1085}
Background: Psychedelic drugs have shown an efficacy in some psychiatric disorders and have an original mechanism of action with a 5-HT2A agonism. Aim: The aim of this meta-analysis was to assess by a quantitative analysis the putative efficacy of psychedelic drugs on depressive symptoms and to investigate the kinetic of this efficacy. Methods: We searched the MEDLINE and PsycINFO databases through April 2019, without limits on year of publication. Means and standard deviations were extracted… 

Figures and Tables from this paper

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
Psilocybin, ayahuasca and LSD all appear to be effective and relatively safe agents capable of producing rapid and sustained improvements in anxiety and depression, and may show a greater efficacy when given to patients over multiple sessions as compared to the more common single session used in many of the existing trials.
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
The strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.
Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
The effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period are quantified and test moderators of these effects are evaluated; adverse effects and risk of bias are evaluated.
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
This research primarily investigates the potential of psychedelics in the treatment of mental health disorders, their short- and long-term effects on recreational users, and the neurological and cognitive processes responsible for their effects.
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
The sum of this research points towards medicinal psychedelics as a potential new class of psychiatric treatments when used within a medically supervised framework with integrated psychotherapeutic support, but before widespread translation into clinical use can occur, appropriately designed and sufficiently powered trials are required to detect both potential positive and negative outcomes.
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
It is demonstrated that single- or two-dose psilocybin administration has rapid and sustained antidepressant effects for up to 6 months, with favorable cardiovascular safety and acceptability.
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
Pre-clinical and clinical evidence of the acute and sustained therapeutic potential of psychedelic therapy in the context of a transdiagnostic dimensional systems framework is reviewed, focusing on the Research Domain Criteria (RDoC) as a template, to assist the field in moving toward a mechanistic understanding of how psychedelics work for patients.
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal
Psychedelic mushrooms in the USA: Knowledge, patterns of use and association with health outcomes
There is a mismatch between the findings of an association between PM use and poor mental health outcomes, and current discourse on the positive health benefits of PM consumption.


Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomised placebo-controlled trial
Evidence of rapid antidepressant effects of a single dosing session with ayahuasca when compared to placebo is observed, and this study is registered with http://clinicaltrials.gov (NCT02914769).
Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Psychedelic-Assisted Group Therapy: A Systematic Review
A systematic review of the published literature in English and Spanish on psychedelic-assisted group therapies aims to stimulate hypotheses to be tested in future research on LSD-assisted psychotherapy, group process, and interpersonal functioning.
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study
The results suggest that ayahuasca may have fast-acting and sustained antidepressive properties and should be replicated in randomized, double-blind, placebo-controlled trials.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
A systematic review of clinical trials published from 1990 until 2015 concluded that ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients.
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
The view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health is bolstered, as data from a clinical trial assessing psilocybin for treatment-resistant depression confirmed this.
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
An overview of past and present models of psychedelic therapy is provided, and important considerations for future interventions incorporating the use of psychedelics in research and clinical practice are discussed.
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.